Oral GLP-1 Deep Dive — Oral Semaglutide vs Orforglipron

Provenance: educational study-synthesis (secondary source)

A clinician-style YouTube review summarising phase-3 trial data on oral vs subcutaneous semaglutide and on orforglipron. Higher quality than the bodybuilding sources (claims map to real trials), but still a secondary source — the underlying trials would be the actual kb-paper evidence. Tagged [educational]. Research/educational use only. Source: YouTube — DHaekq5S340 (Thorough structured capture below; full verbatim not stored.)

Core thesis

Oral GLP-1s get a bad rap, but at correct (higher) doses oral semaglutide is roughly equivalent to standard subQ for most benefits. The catch is dosing and strict administration. Orforglipron is far easier to take but is a non-peptide with different trade-offs.

Semaglutide — structure & why route matters

• Analog of endogenous GLP-1 (a 30–31-aa peptide whose native half-life is ~2 min due to DPP-4 cleavage). Novo Nordisk changed the position-8 amino acid (DPP-4 resistance), changed one other position, and added a fatty-acid chain at position 26 → reversible albumin binding → ~7-day half-life + circulating depot. Same molecule oral or subQ; the difference is purely how much reaches the bloodstream.
• Bioavailability: subQ 89%; oral alone ≈ 0% (degraded in the gut). Co-formulated with SNAC (buffers stomach pH + aids absorption) → 0.4–1% (old) → 1–2% (new formulation). High variability: up to 137% day-to-day in one person (single dose), ~33% at steady state, ~56% between individuals.
• Strict oral administration (to let SNAC work): overnight-fasted, ≤4 oz water only, no food for 30 min (ideally 2 h) after, swallow whole. ~56% of people quit oral semaglutide before 1 year (largely the hassle).

GLP-1 Agonism — receptor locations → effects (great mechanism content)

• Pancreas: ↑ glucose-dependent insulin secretion + ↓ glucagon → blood-sugar control.
• Gut: ↓ motility → slower glucose uptake.
• Hypothalamus/brain: appetite regulation → weight loss (the main weight-loss site).
• Immune cells: anti-inflammatory shift (↓ hs-CRP).
• Kidney cells: chronic-kidney-disease benefit. Endothelial cells: cardiovascular benefit. Brain regions: dementia-risk association. Heart pacing centers: ↑ heart rate (a GLP-1 class effect).

Dose-comparison data (the key tables)

Weight loss (non-diabetic): oral 25 mg → 13.6% (64 wk); oral 50 mg → 15.1% (68 wk); subQ 2.4 mg → 14.9% (68 wk) — essentially equivalent. subQ 7.2 mg (FDA-approved Mar 2026) → 18.7% vs 2.4 mg’s 15.6% head-to-head (~3% more). Benefits plateau above subQ 7.2 mg / oral 25–50 mg (diminishing returns vs rising GI side effects). Orforglipron phase-3 (non-diabetic): 11.2% (72 wk) — ~2.4% less than oral 25 mg, ~3.9% less than 50 mg. Glycemic (A1C): oral 25 mg → −1.8%, oral 50 mg → −2.0%, subQ 2.0 mg → −2.1% (equivalent). Orforglipron highest dose → −1.91%. Cardiovascular: meta-analysis −14% MACE, no difference oral vs subQ; benefit plateaus at low doses. BP ↓ ~6 systolic / 2.5 diastolic across equivalent doses. Lipids: triglycerides ↓, HDL ↑ (orforglipron also ↓ LDL ~5%, semaglutide no LDL effect). hs-CRP: oral 25 mg −46%, 50 mg −57%, subQ 2.4 mg −53%, subQ 7.2 mg −60%. Where subQ has proven edge: chronic kidney disease and fatty-liver disease (direct subQ data; higher oral doses untested but likely similar). Heart failure: even oral 14 mg cut HF hospitalization/death ~41%.

Orforglipron (Foundeo) — the non-peptide oral GLP-1

• Non-peptide small molecule → 79% oral bioavailability, no food/water restrictions, low variability, 29–49 h half-life (steady state in ~1 week). FDA-approved Apr 1; highest studied dose 36 mg ≈ 17.2 mg of the approved formulation.
• Trade-offs: only partial GLP-1 agonism (but biased agonism — avoids the β-arrestin pathway → less receptor desensitization, possibly compensating); cleared hepatically by CYP3A4 → drug-drug interactions + oxidative metabolites (low but non-zero risk); higher off-target potential than peptides (two prior non-peptide GLP-1s — incl. danuglipron — were pulled for liver toxicity). Raises heart rate most of any GLP-1 (~+9 bpm vs +4.5 for oral sema 50 mg) — a mild concern.
• Verdict: the only head-to-head (Lilly-funded, diabetics) compared orforglipron to the old 14 mg semaglutide → orforglipron “superior,” but that’s not the right comparison. Against oral 25 mg+ semaglutide, orforglipron gives less weight loss and lacks the proven end-outcome data (CVD/CKD/HF/dementia). Side effects similar in count but orforglipron’s may be more severe (higher dropout).

Practical takeaways

• If you can follow the strict oral-semaglutide instructions, oral semaglutide 25 mg+ ≈ subQ 2.4 mg for nearly every benefit and is “hands-down” preferred over orforglipron (more studied, proven end-outcomes, peptide safety, fewer drug interactions).
• Orforglipron is the pick if the strict regimen is impractical, or if someone takes oral sema correctly but doesn’t respond (absorption variability).
• Always start low, titrate slow — limits GI side effects, preserves muscle, allows habit change. (Next-video teaser: retatrutide averages ~25% body-weight loss vs ~15% for oral semaglutide.)

New compounds discussed without a note yet (candidates)

• Semaglutide — created with this transcript (was missing).
• Orforglipron (Foundeo) — non-peptide oral GLP-1; candidate (note-type question: it’s a small molecule, not a peptide).
• GLP-1 family still without notes: Liraglutide, Dulaglutide, Survodutide, Mazdutide, Cagrilintide, plus DPP-4 as a concept (the enzyme that degrades GLP-1).